SCHEDULE: State Street Discloses 4.7% Stake in Cytokinetics Inc.

State Street Corporation has reported a 4.7% beneficial ownership stake in Cytokinetics Inc., holding 5,617,334 common shares as of September 30, 2025.

Summary

• State Street Corporation, a Massachusetts-based entity, has filed a Schedule 13G indicating beneficial ownership in Cytokinetics Inc.
• The filing reports an aggregate beneficial ownership of 5,617,334 shares of Cytokinetics Inc. common stock.
• This ownership represents 4.7% of the class of securities.
• State Street Corporation holds shared voting power over 5,262,728 shares.
• State Street Corporation holds shared dispositive power over 5,617,334 shares.
• The event requiring this filing occurred on September 30, 2025.
• State Street Corporation is classified as a parent holding company (HC) for this filing.

Sentiment

Score: 5

Explanation: The filing is a routine regulatory disclosure of beneficial ownership by an institutional investor, indicating a passive stake. It contains factual information without expressing positive or negative sentiment regarding the issuer's performance or prospects.

Positives

• The disclosure of a significant 4.7% stake by a major institutional investor like State Street Corporation can signal institutional confidence in Cytokinetics Inc.'s long-term prospects.
• State Street Corporation's certification that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control, indicates a passive, investment-oriented position.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Cytokinetics Inc.'s future performance or State Street Corporation's investment strategy beyond the passive nature of the holding.

Management Comments

• Elizabeth Schaefer, Senior Vice President, Chief Accounting Officer of State Street Corporation, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of Cytokinetics Inc.

Industry Context

State Street Corporation is a global financial services and bank holding company, widely recognized as a major institutional investor and asset manager. Its disclosure of a significant stake in Cytokinetics Inc. reflects routine portfolio management and broad market participation by large financial institutions in publicly traded companies, including those in the biotechnology or pharmaceutical sectors (assuming Cytokinetics' industry).

Stakeholder Impact

• Shareholders of Cytokinetics Inc. are informed of a significant passive investment by a major institutional entity, State Street Corporation, which may contribute to market stability and investor confidence.
• Potential investors may view the institutional holding as a positive signal, influencing their investment decisions regarding Cytokinetics Inc.

Key Dates

Keywords

Cytokinetics Inc, State Street Corporation, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, Passive Investment